Biogen is replacing CEO Michel Vounatsos, the company said Tuesday, ending a five-year tenure in which he presided over the disastrous approval and rollout of its Alzheimer’s treatment, Aduhelm.
The company also said it is “substantially eliminating” all spending on Aduhelm just 10 months after securing U.S. approval — a concession from the struggling biotech that the drug had become a financial liability following a Medicare decision to restrict patient access and payment.
Drug companies rarely stop marketing a new medicine voluntarily, which makes Biogen’s abandonment of Aduhelm an almost unprecedented setback, particularly for a company with grand ambitions to revolutionize the treatment of Alzheimer’s.
Create a display name to comment
This name will appear with your comment
